Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. (Q37833199)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Martin Köbel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Mark S Carey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Helen Mackay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

David G Huntsman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Vancouver Ovarian Clear Cell Symposium Speakers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

26 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

407-415

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Body size and risk of epithelial ovarian and related cancers: a population-based case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Body size and ovarian cancer: case-control study and systematic review (Australia).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Anthropometry and the risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Endometriosis: candidate genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Racial and ethnic disparities in benign gynecologic conditions and associated surgeries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Ovarian tumors associated with atypical endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

ARID1A mutations in endometriosis-associated ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Mutation of the PIK3CA gene in ovarian and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The SWI/SNF complex and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Highly parallel identification of essential genes in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Calculator for ovarian carcinoma subtype prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The genesis and evolution of high-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Prognostic implication of endometriosis in clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Clear-cell cancer of the ovary-is it chemosensitive?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

PTEN expression in clear cell adenocarcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.005

10.1016/J.YGYNO.2011.01.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21276610%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference